Polymyalgia Rheumatica Market
Number of pages: 100 | Report Format: PDF | Published date: April 26, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.26 billion |
|
Revenue Forecast in 2031 |
US$ 2.09 billion |
|
CAGR |
5.9% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global polymyalgia rheumatica was valued at US$ 1.26 billion in 2022 and is expected to register a revenue CAGR of 5.9% to reach US$ 2.09 billion by 2031.
Polymyalgia Rheumatica Market Fundamentals
Polymyalgia rheumatica (PMR) is a disorder that affects the joints and inflames the muscles, making them stiff and uncomfortable. Other symptoms may include weariness, difficulty sleeping, difficulty moving, sadness, and lack of appetite. Patients with PMR may also develop giant cell arteritis (GCA), also known as temporal arteritis, which affects the arteries in the head and neck, producing discomfort in the form of jaw pain, visual issues, and headaches. Corticosteroids such as prednisolone, Kevzara (sarilumab), and off-label usage of Actemra (tocilizumab) are among the treatments for PMR. Over-the-counter (OTC) pain relievers, disease-modifying anti-rheumatic medicines (DMARDs), and medications to assist in preventing osteoporosis (which can occur while using steroids) are other options.
Polymyalgia rheumatica (PMR) is a prevalent inflammatory condition primarily affecting the elderly. PMR symptoms include bilateral shoulder and hip discomfort, typically accompanied by neck pain and morning stiffness lasting more than 45 minutes. In many situations, the patient recalls the specific day and hour the symptoms first appeared. Weight loss, a fever of unclear cause, overall pain and weariness, and a loss of appetite may round out the clinical picture.
According to the General Practice Research Database, older people with a PMR diagnosis were considerably more likely to obtain a cancer diagnosis in the year after their PMR diagnosis (313/667 cancer cases (69%). This danger was substantially reduced in the experience of other investigators. The biggest distinguishing factors were the type of diagnosis set (territorial, hospital, or university) and the technique used (retrospective research, population database, for example). Furthermore, the increased risk of cancer in the first year following PMR diagnosis seen by some researchers might indicate a mistake.
Although diagnostic procedures are not required to establish a PMR treatment, ultrasound has been shown to increase the specificity of the diagnosis and should thus be considered. Based on retrospective clinical records, several PMR diagnostic criteria have been developed. Most of these involve an age cutoff, bilateral shoulder, and hip girdle discomfort, morning stiffness, and increased inflammatory markers. Due to the lack of specialized PMR testing, doctors frequently rely on a quick response to glucocorticoids (GCs) to confirm the polymyalgia rheumatica diagnosis. Other illnesses that mirror PMR, however, respond to GC treatment as well. There are currently no particular diagnostics for PMR diagnosis. Thus physicians depend on a mix of history, physical examination, laboratory testing, and imaging investigations to reach a polymyalgia rheumatica diagnosis.
PMR incidence increases until the age of 90, with a minor reduction after that: this pattern by age group is evident in all geographical locations, regardless of latitude or socio-environmental factors of the population. Even though there are only a few FDA-approved medications for treating polymyalgia rheumatic musculoskeletal symptoms, a rising number of studies and research on polymyalgia rheumatic musculoskeletal symptoms is likely to develop future growth prospects for significant participants in the polymyalgia rheumatica market.
[77]
Polymyalgia Rheumatica Market Dynamics
The increased global usage of improved diagnostic technology drives the global polymyalgia rheumatica market. The increasing number of studies and research on polymyalgia rheumatic musculoskeletal problems is projected to fuel market expansion. Furthermore, the use of sophisticated diagnostic technologies to examine subacromial and subdeltoid bursitis of the shoulders, hip synovitis, and iliopectineal bursitis to create effective treatments drive market growth. Rapid technical breakthroughs in technologies such as magnetic resonance imaging (MRI) reduce the possibility of mistakes and contribute to a quick and accurate diagnosis of the condition. Physical therapy is gaining popularity with customers since it is incredibly effective and has no negative effects. Physiotherapies are individualized treatments based on the severity of the ailment that aims to reduce muscle stiffness and enhance muscle strength. Thus, the variables are expected to influence market growth throughout the forecast period substantially.
Growing polymyalgia rheumatica patients and increased research and development activity by several pharmaceutical firms are driving revenue growth in the polymyalgia rheumatica therapy market. In the United States, for example, the average yearly incidence of polymyalgia rheumatica (PMR) is 52.5 cases per 100,000 adults aged 50 and higher. Polymyalgia affects between 0.5 and 0.7% of the population. Increased patient knowledge, innovations in treatment choices, and adopting a sedentary lifestyle are some factors impacting polymyalgia rheumatica treatment market revenue growth.
The high costs involved with new medication research and development and the tight rules imposed on drug approval in the market may limit the growth of the polymyalgia industry. Existing medications for treating polymyalgia have various side effects, a barrier to the polymyalgia rheumatic market.
Polymyalgia Rheumatica Market Ecosystem
The global polymyalgia rheumatica market is analyzed from the following perspectives by drug class, distribution channel, and region.
Polymyalgia Rheumatica Market by Drug Class
[56]
Based on the drug class, the global polymyalgia rheumatica is segmented into corticosteroids, disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and others.
The corticosteroids segment showed significant growth during the forecast period. The most common treatment for polymyalgia rheumatica is a modest dose of an oral corticosteroid, such as prednisone (Rayos). Within the first two or three days, they should begin to feel relief from pain and stiffness.
Depending on the symptoms and the results of blood tests, the doctor may gradually reduce the dosage after the first two to four weeks of treatment. Because of the possibility of side effects, the objective is to maintain the dose as low as possible without causing a recurrence of symptoms.
However, the drug's usage requires close monitoring since it can cause major adverse effects such as bone density loss, cataracts, and high blood pressure. This leads to standard diagnostic testing to monitor the disease's effect and treatment, boosting industry growth. Furthermore, the rising need for immune-suppressing drugs such as methotrexate in the early stages of therapy is fueling market expansion.
Polymyalgia Rheumatica Market by Distribution Channel
Based on the distribution channel, the global polymyalgia rheumatica is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacy segment is expected to dominate the market during the forecast. Over the projected period, the hospital pharmacies segment is estimated to hold the largest market share in the global polymyalgia rheumatica market. The availability of new treatments and drugs is expected to stimulate segment growth. Additionally, pharmacists provide standardized and personalized pharmaceutical services to patients to better fulfill their prescription counselling needs and promote adherence and therapeutic efficacy. Because of these considerations, the hospital pharmacy segment accounts for a larger part of the global market. Retail and online pharmacy segments showed the fastest growth during the forecast period.
Polymyalgia Rheumatica Market by Region
Based on the region, the global polymyalgia rheumatica is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Because of significant key players and growing healthcare spending, North America will likely lead the polymyalgia rheumatica market during the forecast period. In the United States, the average incidence of polymyalgia rheumatica (PMR) is 52.5 cases per 100,000 people aged 50 and over. As a result, the high prevalence in these regions is projected to fuel market expansion. Rapid technological advancements such as magnetic resonance imaging (MRI) reduce the risk of mistakes and contribute to a faster and more accurate diagnosis of this ailment. Physical treatment is becoming more popular among consumers due to its great efficacy and absence of side effects. Physiotherapies are tailored treatments that attempt to reduce muscle stiffness and increase muscle strength based on the severity of the ailment. As a result, factors are likely to influence market revenue growth throughout the forecast period significantly.
Asia Pacific is leading the market due to increasing healthcare facilities, many generic manufacturers, and an increase in government efforts and expert communities. The increased incidence of polymyalgia rheumatica and the increase in research and development efforts undertaken by various pharmaceutical firms are driving the expansion of the polymyalgia rheumatica market. Furthermore, increased patient awareness, advancements in treatment choices, and adopting a sedentary lifestyle influence the growth of the polymyalgia rheumatica treatment market.
Polymyalgia Rheumatica Market Competitive Landscape
The global market comprises many market participants operating at regional and global levels. To develop a strong foothold in the market, these competitors pursue strategies such as R&D investments, license agreements, partnerships, mergers and acquisitions, collaborations, and joint ventures. Some of the prominent market players in the global polymyalgia rheumatica market include,
Polymyalgia Rheumatica Market Strategic Developments
Polymyalgia rheumatica (PMR) is a disorder that affects the joints and inflames the muscles, making them stiff and uncomfortable. Other symptoms may include weariness, difficulty sleeping, difficulty moving, sadness, and lack of appetite.
The growing cases of polymyalgia rheumatica and the increase in research and development drive the growth of the global polymyalgia rheumatica market.
The corticosteroids segment led the global polymyalgia rheumatica market.
The revenue CAGR of the polymyalgia rheumatica market during the forecast period will be 5.9%.
Some prominent global polymyalgia rheumatica market players include Horizon Therapeutics Plc (Amgen Inc.), Sanofi SA, Apotex Corporation, and Bristol-Myers Squibb Company
*Insights on financial performance are subject to the availability of information in the public domain